Eris Lifesciences Limited
Healthcare›Healthcare›Pharmaceuticals & Biotechnology›Pharmaceuticals
Key metrics
Price as of 2026-07-17
Stock price
₹1455.40
Market cap
20,157 Cr
Stock P/E
31.9
P/B
5.17
Dividend yield
0.5%
Sign in for full ratios and TTM. Learn about these metrics →
Share price
NSE closing price from historical market data.
Loading price history…
Statement tables · Consolidated
Switches quarterly, P&L, balance sheet, and cash flow. Key metrics and ratios stay on consolidated when available.
Amounts in ₹ Cr · NSE preferred when both exchanges report the same period · tap + to expand rows
Quarterly results
Quarterly · ₹ Cr · tap + rows to expand
| Metric | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 467 Cr | 972 Cr | 1,458 Cr | 2,009 Cr | 720 Cr | 1,455 Cr | 727 Cr | 705 Cr | 773 Cr | 792 Cr | 807 Cr | 757 Cr |
| Operating expenses (approx.) | 296 Cr | 617 Cr | 923 Cr | 1,310 Cr | 468 Cr | 934 Cr | 473 Cr | 445 Cr | 494 Cr | 501 Cr | 543 Cr | 481 Cr |
| EBITDA | 171 Cr | 355 Cr | 535 Cr | 699 Cr | 252 Cr | 521 Cr | 255 Cr | 260 Cr | 279 Cr | 291 Cr | 264 Cr | 276 Cr |
| OPM % | 36.6% | 36.6% | 36.7% | 34.8% | 35.0% | 35.8% | 35.0% | 36.9% | 36.1% | 36.7% | 32.7% | 36.5% |
| Other income | 0.99 Cr | 4 Cr | 9 Cr | 24 Cr | 2 Cr | 13 Cr | 4 Cr | 8 Cr | 3 Cr | 3 Cr | 0.02 Cr | 2 Cr |
| Interest | 17 Cr | 34 Cr | 52 Cr | 85 Cr | 60 Cr | 120 Cr | 57 Cr | 54 Cr | 49 Cr | 50 Cr | 49 Cr | 46 Cr |
| Depreciation | 41 Cr | 83 Cr | 129 Cr | 183 Cr | 76 Cr | 156 Cr | 81 Cr | 77 Cr | 71 Cr | 69 Cr | 70 Cr | 70 Cr |
| Profit before tax | 112 Cr | 239 Cr | 355 Cr | 431 Cr | 115 Cr | 244 Cr | 116 Cr | 129 Cr | 160 Cr | 172 Cr | 145 Cr | 161 Cr |
| Tax % | 16.7% | 9.5% | 10.5% | 7.9% | 22.5% | 24.0% | 25.2% | 20.6% | 22.5% | 22.2% | 25.1% | -74.5% |
| Net profit | 94 Cr | 216 Cr | 317 Cr | 397 Cr | 89 Cr | 186 Cr | 87 Cr | 102 Cr | 125 Cr | 134 Cr | 109 Cr | 279 Cr |
| EPS (₹) | ₹6.97 | ₹16.05 | ₹23.60 | ₹28.82 | ₹6.11 | ₹12.84 | ₹6.15 | ₹6.90 | ₹8.66 | ₹8.82 | ₹7.32 | ₹20.60 |
Profit & loss (annual)
Annual · last column is TTM · ₹ Cr · tap + to expand
| Metric | Mar 2019Standalone only | Mar 2020Standalone only | Mar 2021Standalone only | Mar 2022Standalone only | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Sales | 982 Cr | 1,074 Cr | 1,212 Cr | 1,347 Cr | 1,685 Cr | 2,009 Cr | 2,894 Cr | 3,129 Cr | Sign in for TTM |
| Operating expenses (approx.) | 606 Cr | 690 Cr | 773 Cr | 836 Cr | 1,148 Cr | 1,334 Cr | 1,858 Cr | 2,019 Cr | Sign in for TTM |
| EBITDA | 377 Cr | 384 Cr | 439 Cr | 511 Cr | 537 Cr | 675 Cr | 1,036 Cr | 1,111 Cr | Sign in for TTM |
| OPM % | 38.3% | 35.7% | 36.2% | 37.9% | 31.9% | 33.6% | 35.8% | 35.5% | Sign in for TTM |
| Other income | 32 Cr | 15 Cr | 9 Cr | 26 Cr | 11 Cr | 24 Cr | 18 Cr | 8 Cr | Sign in for TTM |
| Interest | 23 Cr | 2 Cr | 2 Cr | 4 Cr | 26 Cr | 85 Cr | 231 Cr | 193 Cr | Sign in for TTM |
| Depreciation | 36 Cr | 50 Cr | 43 Cr | 65 Cr | 117 Cr | 183 Cr | 315 Cr | 280 Cr | Sign in for TTM |
| Profit before tax | 317 Cr | 331 Cr | 394 Cr | 442 Cr | 405 Cr | 431 Cr | 489 Cr | 638 Cr | Sign in for TTM |
| Tax % | 8.3% | 10.5% | 10.0% | 8.2% | 7.5% | 7.9% | 23.4% | -1.4% | Sign in for TTM |
| Net profit | 291 Cr | 297 Cr | 355 Cr | 406 Cr | 374 Cr | 397 Cr | 375 Cr | 648 Cr | Sign in for TTM |
| EPS (₹) | ₹21.15 | ₹21.61 | ₹26.16 | ₹29.89 | ₹28.10 | ₹28.82 | ₹25.85 | ₹45.33 | Sign in for TTM |
| Dividend payout % | — | — | — | 20.1% | 26.7% | 0.0% | 26.7% | 0.0% | Sign in for TTM |
Sign in for TTM
Trailing twelve months totals and margin rows
Balance sheet
Annual · ₹ Cr · tap + rows to expand
| Metric | Mar 2019Standalone only | Mar 2020Standalone only | Mar 2021Standalone only | Mar 2022Standalone only | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Equity capital | 14 Cr | 14 Cr | 14 Cr | 14 Cr | 14 Cr | 14 Cr | 14 Cr | 14 Cr |
| Reserves | 1,137 Cr | 1,283 Cr | 1,563 Cr | 1,895 Cr | 2,182 Cr | 2,573 Cr | 2,841 Cr | 3,882 Cr |
| Borrowings | — | — | — | — | 830 Cr | 2,735 Cr | 696 Cr | 1,354 Cr |
| Other liabilities | 314 Cr | 183 Cr | 179 Cr | 232 Cr | 617 Cr | 1,092 Cr | 3,065 Cr | 2,116 Cr |
| Total liabilities | 1,470 Cr | 1,483 Cr | 1,755 Cr | 2,150 Cr | 3,667 Cr | 7,049 Cr | 7,033 Cr | 7,366 Cr |
| Fixed assets (net) | 54 Cr | 84 Cr | 75 Cr | 146 Cr | 356 Cr | 505 Cr | 662 Cr | 708 Cr |
| CWIP | 0.75 Cr | 0.0000 Cr | 0.0000 Cr | 0.0000 Cr | 21 Cr | 19 Cr | 67 Cr | 171 Cr |
| Investments | 580 Cr | 320 Cr | 531 Cr | 778 Cr | 37 Cr | 16 Cr | 16 Cr | 10 Cr |
| Other assets | 552 Cr | 451 Cr | 459 Cr | 632 Cr | 769 Cr | 2,308 Cr | 1,268 Cr | 1,593 Cr |
| Total assets | 1,470 Cr | 1,483 Cr | 1,755 Cr | 2,150 Cr | 3,667 Cr | 7,049 Cr | 7,033 Cr | 7,366 Cr |
Cash flows
Annual · ₹ Cr · tap + rows to expand · last column includes FCF
| Metric | Mar 2019Standalone only | Mar 2020Standalone only | Mar 2021Standalone only | Mar 2022Standalone only | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Cash from operating activity | — | — | — | 378 Cr | 292 Cr | 486 Cr | 1,065 Cr | 538 Cr |
| Cash from investing | — | — | — | -320 Cr | -975 Cr | -1,828 Cr | -80 Cr | -369 Cr |
| Cash from financing | — | — | — | -45 Cr | 688 Cr | 1,380 Cr | -881 Cr | -314 Cr |
| Net cash flow | — | — | — | 14 Cr | 5 Cr | 38 Cr | 104 Cr | -145 Cr |
| Free cash flow (OCF − Capex) | — | — | — | 257 Cr | -550 Cr | 357 Cr | 910 Cr | 241 Cr |
Ratios
Ratios as reported or derived per annual period.
| Metric | Mar 2019Standalone only | Mar 2020Standalone only | Mar 2021Standalone only | Mar 2022Standalone only | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| ROCE % | 29.6% | 25.7% | 25.1% | 23.4% | 13.8% | 8.3% | 18.1% | 15.8% |
| ROE % | 25.3% | 22.9% | 22.5% | 21.3% | 17.2% | 12.2% | 10.8% | 15.9% |
| Debtor days | 31 | 50 | 37 | 41 | 63 | 77 | — | — |
| Inventory days | 467 | 311 | 237 | 263 | 336 | 388 | 441 | 487 |
| Days payable | 469 | 427 | 317 | 300 | 319 | 551 | — | — |
| Cash conversion cycle | 29 | -66 | -43 | 4 | 80 | -86 | 441 | 487 |
| Debt / equity | — | — | — | — | 0.38 | 1.06 | 0.21 | 0.35 |
| Current ratio | 1.89 | 3.01 | 2.93 | 3.49 | 1.73 | 0.91 | 0.91 | 0.74 |
| Net debt / EBITDA | 0.00 | 0.00 | 0.00 | 0.00 | 1.44 | 3.91 | 0.48 | 1.17 |
Compare with peers
Loading peers…